Results and Discussion
We constructed genes encoding fusion proteins of the form Med-LexA by integrating LexA DNA at the ends of genes encoding 17 of 25 known Mediator subunits. Each hybrid gene was expressed from its native promoter at its ordinary chromosomal location. Table 1 shows the transcriptional activating function of each fusion measured by b-galactosidase levels expressed from an integrated GAL1-LacZ reporter bearing LexA sites. Only three fusions elicited significant levels of b-galactosidase: those bearing, in addition to LexA, the Mediator subunits Gal11, Med2, and Pgd1. All three of these subunits are found in the tail domain of the Mediator. Figure 1A shows that all three of the fusions that activate transcription-Gall1-LexA, Med2-LexA, and Pgd1-LexA-are unstable as visualized by their degradation following addition of cycloheximide. The figure also shows that, in contrast, fusions bearing either a subunit from the head domain (Srb2) or middle domain (Med1), which do not activate, are not unstable. We did not test the stabilities of other Med-LexA fusions. Figure 1B shows that, whereas the native Gal11 protein is unstable, the native forms of Med2, Pgd1, and LexA are not. We chose Med2-LexA for further study.
As noted in the Summary, Mediator proteins fused to a DNA binding domain (DBD) activate transcription by integrating into the Mediator and recruiting the complex to the promoter by virtue of the attached DBD. This model was supported by the finding that LexA-Gal11 complemented the defect caused by deletion of wild-type (WT) GAL11 [4] . The experiment depicted in Figure S1 , available online, extends this observation to the case of Med2-LexA. Thus, as shown in the figure, Med2-LexA corrects the growth defect caused by deletion of MED2 itself.
We considered the possibility that proteolysis of Med2-LexA occurred only as it activated transcription. One of the experiments depicted in Figure 2 shows that this cannot be so. Thus, although the transcriptional activating activity of Med2-LexA was inhibited (squelched) by overexpression of LexA (Figure 2A ), the fusion protein, expressed at normal levels, remained unstable ( Figure 2B ). Thus, even under conditions in which the fusion protein does not activate transcription, it remains unstable. In contrast to the effect of overexpressing LexA, overexpression of Med2 caused not only an apparent inhibition of the activity of the fusion protein ( Figure 2A ) but also a significant decrease in its levels (Figure 2C ). At these lower levels, the fusion protein remains unstable ( Figure 2C ). The result suggests that a negative autoregulatory effect maintains the concentration of Med2 below some specified level (i.e., at high concentrations, Med2, directly or indirectly, turns off expression of its own gene). Another possibility is that high concentrations of Med2 displace Med2-LexA from the Mediator and thereby, for some reason, render it more sensitive to proteolysis. Figure 3A shows the effect of damaging the 20S proteasome on stability of Med2-LexA. The cells bore the mutations pre1-1 and pre4-1, which render the proteasome heat sensitive, and the cells were grown at a nonpermissive temperature. As shown in the figure, the activator was stabilized under these conditions [9] . Figure 3B shows that the fusion was also stabilized by growth at the nonpermissive temperature of a mutant strain bearing the cdc53-1 temperature-sensitive (ts) mutation [10] . This mutation inactivates, at the high temperature, the scaffold subunit cullin found in the Skp1-Cullin-F-box (SCF) family of E3 ligases.
We introduced Med2-LexA, on a plasmid, into 20 strains, each of which is deleted for or carries a temperature-sensitive mutation in one or another of 20 different F-box proteins. These F-box proteins are known or predicted to be the specificity determinants of the SCF-type E3 ligases [2, 11] . In only one such strain, that bearing deletion of DIA2, was Med2-LexA found to be stable (data not shown). When expressed from its native MED2 promoter, Med2-LexA was also stable in the dia2D strain ( Figure 3C ). Dia2 has not been found to be involved in degradation of any classical transcriptional activator. In this strain, Med2-LexA stimulated production of b-galactosidase from the reporter at least 5-fold less efficiently than it did in a WT strain. The level of LacZ mRNA was also decreased by the dia2 deletion, but the effect was less dramatic than the effect on the protein level ( Figure 3D ). In a control experiment, induction of GAL1 mRNA by Gal4 was identical in WT and dia2-deleted strains (data not shown).
Also not shown, the san1 mutation, which eliminates the protein quality control pathway in the nucleus [12] , had no effect on the stability of Med2-LexA or Pgd1-LexA, the two fusion proteins tested.
We undertook these experiments to challenge the notion that transcriptional activators must be proteolytically unstable to work with full efficiency. We reasoned that, were the instability of classical activators such as Gal4 and Gcn4 some accidental attribute of their activating regions, then an entirely separate class of activators that work in a different way would, in some cases at least, work with full efficiency as stable proteins. But this expectation has been confounded. Of the three Mediator components that work as activators when attached to a DNA binding domain, one (Gal11) is inherently unstable and the other two (Med2 and Pdg1) become unstable when attached to LexA. We do not know why these latter two fusions are unstable-it is possible that instability is some accidental effect of fusing these otherwise stable subunits to LexA. Nevertheless, the instability is required for full activity: where we eliminated a relevant F-box protein (Dia2) and rendered a fusion protein (Med2-LexA) stable, its activating activity was reduced. Thus, our results are consistent with the idea that instability of transcriptional activators contributes to the efficiencies with which they work. Perhaps transcriptional complexes must continually turn over to sequentially bring to the promoter components required for steps leading and subsequent to initiation, and activator instability can help facilitate this turnover. A hint that this idea might be correct was the finding of Muratani et al. [2] that stabilization of Gal4 (caused by deleting DSG1) has a much greater effect on translation of the mRNA read from the promoter than it does on mRNA production itself. They further showed that the Pol II recruited by Gal4 working in the dsg1 mutant was deficient in Ser5 phosphorylation of its carboxy-terminal domain and in recruitment of the mRNA capping complex. We find here (see Figure 3D ) that increasing the stability of Med2-LexA (by deleting DIA2) preferentially decreased the amount of translated protein compared to that of the mRNA elicited by the fusion activator.
An additional finding reported here is that, among a wide array of Med-LexA fusion proteins tested, only those bearing one of three subunits from the Mediator tail domain work efficiently as activators. An array of previous reports has suggested that components of the tail domain (and in particular Gal11) are targets of transcriptional activating regions [4] [5] [6] [7] [8] [13] [14] [15] . The results, taken with those presented here, might reflect some stereospecific restrictions on how recruitment can be successfully effected, either by a classical or a nonclassical activator, to build a transcriptional complex.
Experimental Procedures Yeast Strains and Plasmids
The parental Saccharomyces cerevisiae strain used in most of this study is JPY5 (MATa, ura3-52 his3D200 leu2D1 trp1D63 lys2D385), which was derived from the S288C background [4] . The cdc53-1 strain and its corresponding wild-type strain were derived from the W303 background [16] . The pre1-1 pre4-1 strain and its corresponding wild-type strain were obtained from Pengbo Zhou [17] . Strains bearing Myc-tagged MED2 or PGD1 were constructed via a standard method [18] , and a modified version of this method, which involves replacing Myc with LexA, was used to construct strains expressing the Med-LexA fusion proteins. The med2D and dia2D strains were constructed by deleting their corresponding open reading frames via a one-step replacement method [18] . Genes encoding each of the indicated Mediator subunits were fused, at their 3 0 ends, to the LexA gene. Each fusion protein was expressed in a strain bearing an integrated reporter comprising two LexA sites upstream of GAL1-LacZ gene. Cells were grown overnight and were assayed for b-galactosidase activity. The expression levels and stabilities of five fusions were tested and are shown in Figure 1 . The reporter plasmid for integration carrying two LexA sites upstream of GAL1-LacZ was described previously [4] . A plasmid overexpressing Med2-LexA from the ACT1 promoter was constructed by inserting the MED2 gene into a plasmid bearing the LexA gene attached to the ACT1 promoter [4] .
Cell Growth Assays
Cells were grown overnight to mid-log phase in YPD media and were washed and diluted with water to 0.1 at OD600. Then a series of 103 dilutions were made, and 5 ml of each dilution was spotted on YPD (Glucose) and YPGal (Galactose) plates. Pictures were taken after cells were grown at 30 C for 3 days.
b-Galactosidase Assays b-galactosidase activity was measured as described previously [19] . Each assay was performed at least in duplicate, and the standard error was less than 20%. Relative activities are reported with average WT activity set to 1.
Cycloheximide Chase Assays
Protein degradation was assessed by cycloheximide chase assays as described in Muratani et al. [2] . Cells were grown in appropriate synthetic complete media containing 2% glucose overnight to mid-log phase. Then cycloheximide was added to the culture (50 mg/ml final concentration), samples were taken at the indicated time points, and steady state levels of protein of interest were visualized by western blotting with appropriate antibodies. The antibodies used were anti-LexA (ab14553 from Abcam), anti-Carboxypeptidase Y (CPY, A6428 from Molecular Probes), anti-Med2 (sc-28058 from Santa Cruz Biotechnology), anti-Myc (sc-40 from Santa Cruz Biotechnology), and anti-Gal11 (generated in our laboratory). In cases in which temperature-sensitive mutants were involved, WT and ts cells were grown at the permissive temperature (25 C) overnight to mid-log phase and then shifted to the restrictive temperature (37 C) for 1 hr before cycloheximide was added.
Reverse Transcriptase-Polymerase Chain Reaction Analysis RNA was extracted, reverse transcribed, and quantified by reverse transcriptase-polymerase chain reaction, as described previously [20] . Relative -gal activity
Relative LacZ mRNA Wild-type (WT) and pre1-1 pre4-1 cells (which bear double mutations of the 20S proteasome subunits), both bearing the MED2-LexA fusion gene, were grown overnight to mid-log phase at 30 C and then shifted to 37 C for 1 hr. A cycloheximide chase experiment was performed. (B) Inactivation of an SCF-type E3 ligase. WT and cdc53-1 (which bears a mutation in the cullin subunit of SCF-type E3 ligases) cells, both bearing the MED2-LexA fusion gene, were grown overnight to mid-log phase at 30 C and then shifted to 37 C for 1 hr. A cycloheximide chase experiment was performed. (C) Stability of Med2-LexA in a strain deleted for the specific E3 F-box protein Dia2. Cells deleted or wild-type for DIA2 (which encodes an F-box protein), and also bearing the MED2-LexA fusion gene, were exposed to cycloheximide as assayed in the experiments depicted in Figure 1 . (D) Activity of Med2-LexA in a strain deleted for DIA2. WT and dia2D cells, both bearing MED2-LexA fusion gene, were assayed for both b-galactosidase activities and LacZ mRNA levels. b-galactosidase activity and LacZ mRNA level in WT cells were set to 1. Error bars denote standard deviation. 
